Business Context and Reporting Period
This Form 8-K filing by Apyx Medical Corp (APYX) covers events occurring between November 4, 2024, and November 8, 2024. The company, a medical device manufacturer, reported significant corporate actions including a credit agreement amendment, a registered direct offering of equity, and major executive and board restructuring.
Key Financial Metrics and Capital Events
- Capital Raise: The company completed a registered direct offering on November 8, 2024, raising approximately $7 million in gross proceeds. This included the sale of 3,000,000 shares of Common Stock at $1.18 per share and pre-funded warrants for up to 2,934,690 shares at $1.179 per warrant.
- Debt Restructuring: On November 7, 2024, the company amended its Credit Agreement with Perceptive Credit Holdings IV, LP. The amendment reduced Minimum Advanced Energy Net Revenue Targets for quarterly periods from September 30, 2024, through September 30, 2028.
- Operating Expense Covenants: The amended credit agreement imposes operating expense caps of $40,000,000 for the fiscal year ended December 31, 2025, and $45,000,000 for the fiscal year ended December 31, 2026.
- Liquidity: The filing does not provide specific current cash balances or liquidity ratios. Proceeds from the offering are designated for working capital and general corporate purposes.
Material Changes and Personnel Actions
The company executed a cost-saving and restructuring program resulting in significant leadership changes:
- Board Resignations: John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors effective November 4, 2024. The Board size was reduced from eight to five directors.
- Executive Appointment: Shawn D. Roman was appointed Chief Operating Officer (COO) effective November 6, 2024, with an annual base salary of $305,761. He previously served as Vice President of Research and Development.
- Executive Termination: Todd Hornsby, Executive Vice President of Sales and Marketing, was terminated without cause effective November 4, 2024. His responsibilities were assumed by CEO Charlie Goodwin. Mr. Hornsby is eligible for severance payments subject to a general release.
Guidance, Risks, and Contingencies
- Financial Guidance: The filing does not contain updated forward-looking financial guidance or revenue projections beyond the revised revenue targets in the credit agreement.
- Conditions Precedent: The credit amendment was contingent upon the company receiving $5,000,000 in net cash proceeds from the equity issuance and issuing 150,000 shares of common stock to Perceptive as part of the transaction.
- Ownership Limitations: The pre-funded warrants issued in the offering are subject to a 9.99% beneficial ownership limitation, preventing holders from exercising if it would exceed this threshold.
Key Facts for Investor Verification
- Verify the exact net proceeds from the $7 million gross offering after deducting transaction expenses.
- Confirm the specific details of the reduced "Minimum Advanced Energy Net Revenue Targets" in the amended Credit Agreement (Exhibit 10.1).
- Review the Q3 2024 earnings press release (Exhibit 99.1) for detailed revenue and profit metrics, as this 8-K only references the release without restating the numbers.
- Monitor the company's ability to meet the new operating expense caps of $40 million (2025) and $45 million (2026) to avoid default on the credit facility.